Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Who May Qualify: - Biopsy proven cancer of the pancreas, gallbladder or biliary tract, stomach, small bowel, colon, rectum, or appendix with extensive or irresectable peritoneal carcinomatosis - Estimated life expectancy \> 6 months; \> 3 months if primary cancer is pancreatic - Age ≥ 18 years - Adequate performance status (Karnofsky index \> 60% and WHO performance status \< 2) - Written willing to sign a consent form obtained prior any act of the research Who Should NOT Join This Trial: - Concomitant systemic (IV) treatment with irinotecan (either as monotherapy or as part of a combination regimen such as FOLFIRI, CAPIRI, or FOLFOXIRI) - Pregnancy or breastfeeding during the clinical study - Patients of childbearing age unable or unwilling to provide effective contraception during the study and until the end of relevant exposure (extended by 30 days (female participants) or 120 days (male participants) since the IMP is genotoxic). - Known allergy or intolerance to irinotecan - Significant amount of ascites detectable (exceeding 3l in volume) - Intestinal or urinary tract obstruction - Extensive hepatic and/or extra-abdominal metastatic disease - Impaired renal function (serum creatinine \> 1.5 mg/dl or calculated GFR (CKD-EPI) \< 60 mL/min/1.73 m² - Impaired liver function (serum total bilirubin \> 1.5 mg/dl, except for known Gilbert's disease) - Platelet count \< 100.000/µl - Hemoglobin \< 9g/dl - Neutrophil granulocytes \< 1.500/ml - Patients known to use: - CYP3A4 inducers (rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, St John's wort) - inhibitors of CYP3A4 (clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (atazanavir, gemfibrozil, indinavir, regorafenib) Always talk to your doctor about whether this trial is right for you.